BioSyent Inc. (OTCMKTS:BIOYF – Get Free Report) was the target of a significant growth in short interest in the month of January. As of January 31st, there was short interest totalling 3,900 shares, a growth of 225.0% from the January 15th total of 1,200 shares. Based on an average trading volume of 14,800 shares, the days-to-cover ratio is presently 0.3 days.
BioSyent Stock Performance
BioSyent stock traded up $0.01 during mid-day trading on Friday, reaching $7.82. 230 shares of the company’s stock were exchanged, compared to its average volume of 4,920. The business’s fifty day simple moving average is $7.84 and its 200 day simple moving average is $7.85. BioSyent has a one year low of $5.93 and a one year high of $8.90.
BioSyent Cuts Dividend
The business also recently declared a dividend, which was paid on Monday, December 16th. Stockholders of record on Monday, December 2nd were paid a dividend of $0.0322 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend was Friday, November 29th.
BioSyent Company Profile
BioSyent Inc, together with its subsidiaries, acquires or licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX Pd Therapeutic 150 for the treatment of iron deficiency anemia; FeraMAX Pd Maintenance 45, a chewable supplement for the prevention of iron deficiency anemia; and FeraMAX Pd Powder 15, a powder form product used for preventing iron deficiency and iron deficiency anemia.
Featured Stories
- Five stocks we like better than BioSyent
- Top Stocks Investing in 5G Technology
- Up 50% in January, Twilio’s Pullback is the Time to Buy
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Watch These 3 Stocks—High Short Interest and Big Upside Potential
- What is the Nikkei 225 index?
- Cisco Roars Back: Is the Tech Giant Reborn?
Receive News & Ratings for BioSyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioSyent and related companies with MarketBeat.com's FREE daily email newsletter.